Multiple Myeloma Clinical Trials in Boston, Massachusetts

31 studies are recruiting for multiple myeloma in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

   The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   50 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05201781 on ClinicalTrials.gov

2. Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia

   Pivotal study to validate the diagnostic performance of PointCheck, the first non invasive device to preliminary detect neutropenia in cancer patients receiving intermediate/high risk antineoplastic therapy.

   Stage

   Not phased

   Ages

   10 and older

   Site

   Massachussetts General Hospital, Boston, Massachusetts

   Locations

   6 in total

   Run by

   Leuko Labs, Inc.

   See if you can join NCT06323447 on ClinicalTrials.gov

3. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   157 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07258511 on ClinicalTrials.gov

4. ELEVATE-MM: Elotuzumab, Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

   The aim of this research study is to evaluate the safety and tolerability of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma. The names of the study drugs involved in this study are: * Iberdomide (a type of cereblon E3 liga…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Beth Israel Deaconess Medical Center, Boston, Massachusetts

   Locations

   3 in total

   Run by

   Omar Nadeem, MD

   See if you can join NCT06518551 on ClinicalTrials.gov

5. Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

   This study is comprised of a main study, an observational study, and optional survey studies. The main study is being done to see whether using Duffy null specific treatment dosing guidelines can reduce or delay dose modifications and avoid neutropenic fever (fever in the setting of low neutrophils…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Andrew Hantel, MD

   See if you can join NCT07341867 on ClinicalTrials.gov

6. AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

   This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics and efficacy of AZD0305 as monotherapy and in combination with other anticancer agents in participants with MM.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Boston, Massachusetts

   Locations

   46 in total

   Run by

   AstraZeneca

   See if you can join NCT06106945 on ClinicalTrials.gov

7. A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

   This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   60 in total

   Run by

   C4 Therapeutics, Inc.

   See if you can join NCT07284758 on ClinicalTrials.gov

8. A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

   Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and change in disease activity of surzetoclax in adult participants with relapsed/refractory (R/R) MM. Adverse events and change in…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute /ID# 271846, Boston, Massachusetts

   Locations

   51 in total

   Run by

   AbbVie

   See if you can join NCT06953960 on ClinicalTrials.gov

9. A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

   A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   29 in total

   Run by

   K36 Therapeutics, Inc.

   See if you can join NCT05651932 on ClinicalTrials.gov

10. D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM

    The purpose of the study is to determine the best treatment approach based on the risk profile of the cancer cells and on how the disease responds to treatment. This is a randomized research study evaluating treatment for transplant-eligible participants with newly diagnosed multiple myeloma (NDMM)…

    Stage

    Phase 3

    Ages

    18 to 75

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Locations

    3 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT07624513 on ClinicalTrials.gov

11. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

    This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Tufts Medical Center, Boston, Massachusetts

    Locations

    212 in total

    Run by

    European Myeloma Network B.V.

    See if you can join NCT05243797 on ClinicalTrials.gov

12. Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

    The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    52 in total

    Run by

    Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

    See if you can join NCT06297226 on ClinicalTrials.gov

13. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

    The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Tufts Medical Center, Boston, Massachusetts

    Locations

    173 in total

    Run by

    Janssen Research & Development, LLC

    See if you can join NCT07518186 on ClinicalTrials.gov

14. Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

    Doctors leading this study hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to people who have multiple myeloma that has gotten worse and is not responding to standard drugs that are used for treating multiple my…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Beth Israel Deaconess Medical Center, Boston, Massachusetts

    Locations

    2 in total

    Run by

    University of Chicago

    See if you can join NCT05789303 on ClinicalTrials.gov

15. Elranatamab in R/R Multiple Myeloma

    This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    3 in total

    Run by

    Massachusetts General Hospital

    See if you can join NCT06138275 on ClinicalTrials.gov

16. MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

    The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments befo…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Beth Israel Deaconess Medical Center, Boston, Massachusetts

    Locations

    270 in total

    Run by

    Pfizer

    See if you can join NCT06152575 on ClinicalTrials.gov

17. A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

    The study consists of three parts: * Part 1: The primary purpose of this part aims to evaluate the safety, tolerability, and clinical activity of escalating doses of single agent belantamab in participants with refractory multiple myeloma (RRMM) who have received at least 3 prior therapies (4L+). *…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    GSK Investigational Site, Boston, Massachusetts

    Locations

    44 in total

    Run by

    GlaxoSmithKline

    See if you can join NCT05714839 on ClinicalTrials.gov

18. Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

    The purpose of this study is to test the anti-cancer activity of Teclistamab and to compare it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple myeloma. People with smoldering multiple myeloma (SMM) usually do not have symptoms but are at risk for progressi…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Dana Farber Cancer Institute, Boston, Massachusetts

    Locations

    3 in total

    Run by

    Irene Ghobrial, MD

    See if you can join NCT05469893 on ClinicalTrials.gov

19. A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

    The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Beth Israel Deaconess Medical Center, Boston, Massachusetts

    Locations

    19 in total

    Run by

    Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

    See if you can join NCT06121843 on ClinicalTrials.gov

20. Selinexor and Backbone Treatments of Multiple Myeloma Patients

    This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to b…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana Farber Cancer Institute, Boston, Massachusetts

    Locations

    25 in total

    Run by

    Karyopharm Therapeutics Inc

    See if you can join NCT02343042 on ClinicalTrials.gov

21. A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

    This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that r…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana Farber/Harvard Cancer Center, Boston, Massachusetts

    Locations

    42 in total

    Run by

    Regeneron Pharmaceuticals

    See if you can join NCT05137054 on ClinicalTrials.gov

22. A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

    The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. In addition, the researchers will find out whethe…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Tufts Medical Center (Data Collection Only), Boston, Massachusetts

    Locations

    11 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06083922 on ClinicalTrials.gov

23. DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM

    This study is to evaluate the safety and effectiveness of dendritic cell DC/MM fusion vaccine in combination with standard of care B-cell maturation antigen (BCMA) CAR-T cell therapy in participants with relapsed/refractory multiple myeloma. The names of the study drugs involved in this study are: …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Beth Israel Deaconess Medical Center, Boston, Massachusetts

    Run by

    David Avigan

    See if you can join NCT07377435 on ClinicalTrials.gov

24. A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

    This research is being done to determine if the combination of the Dendritic Cell (DC)/ Multiple Myeloma (MM) fusion vaccine with elranatamab is safe and effective in treating Relapsed or Refractory Multiple Myeloma (MM). The names of the study drugs and vaccine involved in this study are: * DC/MM …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Beth Israel Deaconess Medical Center, Boston, Massachusetts

    Locations

    2 in total

    Run by

    David Avigan

    See if you can join NCT06799026 on ClinicalTrials.gov

25. Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

    This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.

    Stage

    Phase 1

    Ages

    13 and older

    Site

    Dana Farber Cancer Institute, Boston, Massachusetts

    Locations

    8 in total

    Run by

    Newave Pharmaceutical Inc

    See if you can join NCT04771572 on ClinicalTrials.gov